BCRlabl is a chimeric oncogene implicated in the pathogenesis of human chronic myelogenous leukemia. Expression of the BCRlabl gene induces hematologic malignancies in transgenic mice and transformation of interleukin-3-dependent hematopoietic cells. The mechanism of BCRlabCmediated transformation of hematopoietic cells is poorly understood and involves activation of at least two signaling pathways, p21"* and PI 3-kinase. Here we report that PI 3.4-P2 and PI 3,4,5-P3, the enzymatic products of PI 3-kinase, accumulate in metabolically labeled transformed hematopoietic cells, in contrast t o our previous report on the lack of accumulation of PI 3-kinase products in nontransformed NIH 3T3 fibroblasts that express p210 BCR/abl. Transformed cells also have increased PI 3-kinase activity in total cell extracts and membrane fractions. Activation of PI 3-kinase occurs by occupancy of SH2 domains of PI 3-kinase regulatory subunit, p85, by phosphorylated YXXM motifs. Therefore, we investigated whether BCR/abl binds t o p85 and whether HRONIC myelogenous leukemia (CML) and nearly one third of acute lymphocytic leukemias (ALL) are characterized by a reciprocal chromosomal translocation (9;22) which has not been reported in solid tumors. This translocation is frequently detected as the Philadelphia chromosome and results in expression of chimeric BCWabl proteins of 210 kD in CML and 185 kD in ALL. Amino-terminal sequences of BCWabl are derived from a breakpoint cluster region on chromosome 22 (BCR) and the carboxyl-terminal is provided by the proto-oncogene c-ab1 on chromosome 9.'.2 The tyrosine kinase activity of c-abl is activated and is cmcia1 for the transforming capacity of BCWabl.* Expression of CML transforming oncogene, p210 BCW abl, leads to growth-factor independence and transformation of hematopoietic cells.'" In contrast, p210 BCWabl is not transforming for NIH3T3 fibroblasts3 and weakly transforming for Rat-l fibroblasts.' The BCWabl gene product is cytosolic9-" and expression of a mutant that contains an amino-terminal viral gag sequence in fibroblasts results in targeting a portion of the protein to the plasma membrane.'* The gag p210 BCWabl gains the ability to transform The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1996 by The American Society of Hematology. 0006-4971/96/8805-0048$3.00/0 1542 this binding is mediated by interaction of p85 SH2 domains with YXXM motif of BCR/abl. Association of p210 BCR/abl with p85 in immune complexes and with p85 SH2 domains was evident in hematopoietic cells that express the wt p210 BCR/abl. However, the binding of BCR/abl t o p85 SH2 domains was abolished in cells expressing mutant, temperature-sensitive (6) p210 BCRlabl in which the tyrosine in the YXXM motif of p210 BCRlabl was replaced by histidine. Despite lack of direct interaction with p85 SH2 domains, expression of ts p210 BCR/abl resulted in rapid, time-dependent activation of total and membrane-associated PI 3-kinase and increased PI 3-kinase activity in anti-Ftyr and anti-ab1 immunoprecipitates. These data suggest that BCR/abl-induced activation of PI 3-kinase in hematopoietic cells does not require binding of p85 SH2 domains t o BCR/ ab1 gene product and involves interaction with other tyrosine phosphorylated intermediate proteins.
HRONIC myelogenous leukemia (CML) and nearly one third of acute lymphocytic leukemias (ALL) are characterized by a reciprocal chromosomal translocation (9;22) which has not been reported in solid tumors. This translocation is frequently detected as the Philadelphia chromosome and results in expression of chimeric BCWabl proteins of 210 kD in CML and 185 kD in ALL. Amino-terminal sequences of BCWabl are derived from a breakpoint cluster region on chromosome 22 (BCR) and the carboxyl-terminal is provided by the proto-oncogene c-ab1 on chromosome 9.'. 2 The tyrosine kinase activity of c-abl is activated and is cmcia1 for the transforming capacity of BCWabl.* Expression of CML transforming oncogene, p210 BCW abl, leads to growth-factor independence and transformation of hematopoietic cells.'" In contrast, p210 BCWabl is not transforming for NIH3T3 fibroblasts3 and weakly transforming for Rat-l fibroblasts.' The BCWabl gene product is cytosolic9-" and expression of a mutant that contains an amino-terminal viral gag sequence in fibroblasts results in targeting a portion of the protein to the plasma membrane.'* The gag p210 BCWabl gains the ability to transform 
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Plasma membrane association also determines the transforming ability of src protein-tyrosine kinaseI4 and has been postulated to be important for mitogenic signaling in adherent cells. The inability of NIH 3T3 fibroblasts to be transformed by p210 BCWabl tyrosine kinase has been attributed to its cytosolic localization, which could impair access of PI 3-kinase and other signaling proteins to its substrates. However, the expression of cytosolic p210 BCWabl in hematopoietic cells'' escapes this requirement. We have previously described association of BCWabl with PI 3-kinase activity in fibroblasts that express nontransforming or transforming abl variants. However, accumulation of PI 3-kinase products is detected only in v-ab1 and gagp210 BCWabl transformed NIH 3T3 fibroblasts and not in nontransformed fibroblasts that express the wild-type (wt) p210 BCWabl." Association of BCWabl with PI 3-kinase activity has been reported in primary CML cells and expression of PI 3-kinase regulatory subunit, p85, was found to be essential for proliferation of bone marrow (BM) cells from patients with CML and BCIUabl-transformed hematopoietic cell lines."
Mammalian PI 3-kinase is a heterodimeric protein that consists of an 85-kD regulatory subunit which contains one SH3 and two SH2 domains, and a 110-kD catalytic subunit. Activation of PI 3-kinase correlates with cellular transformation by protein-tyrosine kinases, including BCWabl.'"'8 ACcumulation of 3'-phosphorylated polyphosphoinositides is found in response to many mitogenic signals, although their precise targets are not clearly defined. PI 3-kinase activity is inactive in quiescent cells and can be activated by interaction of p85 SH2 domains with phosphorylated tyrosines in YXXM motifs.'6.'9-2' In this study we found that PI 3-kinase activation and association with BCWabl protein occurs in murine hematopoietic cells which express p210 BCWabl gene product and tested whether the YXXM motif present in BCWabl sequence is necessary for activation of P1 3-kinase. We used p210 BCWabl mutant that has a mutation of tyrosine in the YXXM motif. The wt BCWabl bound to p85 SH2 domains but this interaction was abolished in cells expressing ts BCWabl mutant. Despite lack of direct interaction with p85, we found that PI 3-kinase activation occurs in cells that express ts BCWabl mutant after the shift to permissive temperature.
MATERIALS AND METHODS
Cell lines and cell culture. The following fibroblast cell lines were used: parental NIH3T3 fibroblasts, nontransformed 3T3p210 cells that stably express wt p210 BCFUabl, and transformed 3T3gp210 cells that express gagp210 BCFUabl mutant. ' The hematopoietic cells used were: parental pro-B lymphocyte cell line, BaF3; BaFp210, which expresses wt p210 BCWabl; and BaF-ts p210, which expresses ts p210 BCR/abl. The construction of plasmids and generation of stably transfected cell lines have been Murine pro-B lymphocytes, BaF3, grew only in medium containing IL-3, whereas BaF3 cells that stably express BCR/ ab1 (Bp210) were growth factor-independent. 6 NIH 3T3 fibroblasts were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO, Grand Island, NY) containing 10% calf serum. Before harvest, fibroblast cell lines were deprived of growth factors in DMEM containing 1% bovine serum albumin (BSA) for 24 hours. Soft-agar assays for anchorage-independent growth were performed as de~cribed.'~ Parental BaF3 cells were grown in suspension culture in RPM1 1640 medium containing 10% fetal calf serum (FCS) and 10% to 20% conditioned medium from the L-3-producing cell line, WEHI 3B. Factor-independent Bp210 cells were grown without IL-3 supplementation. To induce quiescence without affecting viability, all hematopoietic cells were incubated for 14 to 16 hours in R P M medium containing 0.5% FCS supplemented with 0.1 % WEHI-conditioned medium for IL-3-dependent cells before harvest. Under these conditions, cell viability was maintained at over 90%.24
Metabolic labeling of intact cells. Cells were grown to a density of 2 X lo6 cells/mL, deprived of growth factor for 10 hours, and metabolically labeled with 'zP-orthophosphate in phosphate-free DMEM (GIBCO) at 0.5 mCi/mL for the last 3 hours as de~cribed.'~ Identification of PI 3-kinase products by high-performance liquid chromatography (HPLC). Phospholipids were extracted and deacylated as described with modifications for "P labeling of hematopoietic ~e l l s .~~-~~ In brief, polyphosphoinositides extracted into chloroform phase were dried under nitrogen, deacylated in 1 mL of methylamine reagent (40% methy1amine:water:methanol:n-butanol; 26.7: 16:45.7: 1 1.6). dried in vacuo, and subjected to HPLC separation on Partisphere SAX column (5 mm; Whatman, Clifton, NJ) using a 0 to 1 m o a modified ammonium phosphate gradient." Commercially available 'H-polyphosphoinositides were deacylated as described above and used as standards. Elution of adenosine triphosphate and adenosine diphosphate was monitored by UV.
Cell extraction and subcellular fractionation. Whole-cell lysates (WCL), cytosol, and mixed membrane fractions from NIH 3T3 fibroblasts and hematopoietic cells were prepared as previously described." PI 3-kinase assay. PI 3-kinase activity from immunoprecipitates, 1,000-fold diluted whole-cell extracts (total activity), and subcellular fractions (cytosol and solubilized particulate fractions) was measured as described." Enzymatic activity was expressed as picomoles of phosphate incorporated into PIPJmidmg of protein (units per milligram; U/mg).
Expression andpur$cation of GST-fusionproteins. p85-C-SH2-GST-fusion protein was expressed in Escherichia coli and affinity purified as d e s c~i b e d ?~.~~ lmmurwprecipitations, binding assays, and Western blotting. Anti-rat p85 rabbit antiserum and anti-P-Tyr antibodies were purchased from U B I (Lake Placid, NY). Monoclonal anti-ab1 antibodies (c-abl, Ab-3) were from Oncogene Science (Cambridge, MA). Polyclonal anti-abl F'GeX 4 antibodies were a gift of R. Van Etten (Harvard Medical School, Boston, MA). For immunoprecipitations, WCL were incubated with appropriate antibodies for 2 hours at 4°C followed by addition of protein A-agarose (Sigma, St Louis, MO) for 45 minutes. Immune complexes were sequentially washed five times with 3 x phosphate-buffered saline (PBS), 1X TNJ3 (10 mmoVL TridHC1, pH 7.4, 100 mmoVL NaCI, 1 mmoVL EDTA) and once in PBS. Immunoprecipitates were used for PI 3-kinase assay or denatured by boiling for 3 minutes in gel-loading buffer and resolved by electrophoresis on 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels.
For glutathione S-transferase (GST)-fusion protein binding assays, WCLs from cells expressing wt and is BCWabl normalized for expression of BCWabl (2 and 1.5 mg protein, respectively) were incubated with 1.5 pg of immobilized GST-fusion proteins at 4°C for 2 hours. The complexes were washed three times with HNTG buffer (20 mmoVL HEPES, pH 7.5, 150 mmoVL NaCI, 0.1% Triton X-100, 10% glycerol, 50 mmol/L NaF, 1 mmoVL Na3V04)" and separated on SDS-polyacrylamide gel electrophoresis (PAGE).
Proteins resolved on SDS-PAGE were electrophoretically transferred onto either hydrophobic PVDF (Qiagen, Chatsworth, CA) or nitrocellulose membranes (Pharmacia, Piscataway, NJ). The membranes were blocked in PBS-T (0.2% Tween-20/7% nonfat dry milk) and 2% BSA for 1 hour and probed with specific antibodies and horseradish peroxidase (HRP)-conjugated secondary antibodies. Immunoreactive bands were visualized by using ECL kit (Amersham, Arlington Heights, IL).
RESULTS
Characterization of cell lines and expression of BCWabl gene products. To ensure that all cell lines which express BCWabl constructs did not change their properties during culture, we examined their morphology, anchorage-independent growth, and expression of BCWabl gene products. Consistent with their nontransformed phenotype, parental and nontransformed NIH 3T3 fibroblasts (NIH 3T3 and 3T3p210) exhibited flat morphology and failed to grow in soft agar (Fig 1) . The transformed phenotype of fibroblasts that express gag-BCWabl (3T3gp210) was manifested by rounded shape, semi-adherence, formation of foci, and anchorage-independent growth in soft-agar (Fig 1C and F) . Hematopoietic Bp210 cells were approximately two times larger than BaF3 parental cells (Fig 1G and H ). BaF3 and 32D cells expressing rs BCWabl required L -3 when grown at nonpermissive (39°C) temperature, were growth factorindependent at 33°C as previously reported:' and did not show change in size after growing for 24 hours at permissive temperature compared with parental cells.
The expression of BCWabl variants was examined by Western blotting. Equal amounts of protein from WCLs were immunoblotted using a monoclonal anti-ab1 antibody. BCW ab1 transformed BaF3 cells had consistently lower levels of p210 expression than did NIH3T3 fibroblasts (Fig 2A, lanes  2 and 5) . Therefore, the level of expression of BCWabl protein did not correlate with transformation. The 195-kD anti-ab1 immunoreactive band seen in lysates from gag- The level of ts p2 I O BCWabl mutant increased after shift of cells to 33°C with a less than twofold increase after 24 hours compared with cells grown at 39°C or to stably transformed cells that express wt p210 BCWabl (Fig 2B) . Expression of ts p210 BCWabl was maintained in the absence of growth factor for at least 14 days of culture at 33°C. The shift of cells to permissive temperature was associated with marked increase in tyrosine phosphorylation of intracellular substrates, which was evident within 15 minutes at 33°C (Fig 2C) .
Accumulation of PI 3-kinase products in p210 BCWabl transformed hematopoietic cells. Targeted expression of gag BCWabl in NIH 3T3 fibroblasts to the plasma membrane results in fibroblast transformation.' and accumulation of PI 3-kinase products.'.' To confirm whether PI 3-kinase activation occurs in BCWabl-transformed hematopoietic cells, we measured the levels of PI 3-kinase products in hematopoietic cells that express p210 BCWabl. Table 1 summarizes the levels of 3'-phosphorylated polyphosphoinositides in metabolically labeled cells. An increase in highly phosphorylated PI 3-kinase products, PI 3,4-P2 and PI 3,4,5-P3 (PIP3), was observed in BCWabl-transformed hematopoietic cells compared with parental cells. Between 1.5 and 2.5 X IO5 dpm of 32P was incorporated into the major polyphospoinositides, PI 4-P and PI 4,5-P2. No change in the content of PI 3-P was observed (not shown), consistent with results reported in other cells and in NIH 3T3 fibroblasts transformed by vab1 or BCWabl.1.'.16 PI 3-kinase activity and p85 content in total cell extracts and subcellular fractions. To determine whether the accumulation of 3'-phosphorylated polyphosphoinositides in hematopoietic cells was caused by an increase in PI 3-kinase activity or by altered content or distribution of p85, we analyzed PI 3-kinase activity and p85 content in total cell extracts and in subcellular fractions. In agreement with our previous observation^,^' 1% NP-40 extracts of resting NIH3T3 cells contained 25 to 30 U of PI 3-kinase activity per milligram of protein (Table 2 ). Hematopoietic cells that express wt or ts BCWabl grown at permissive temperature for 24 hours had a 6 4 % and 96% increase in total PI 3-kinase activity, respectively. These results correlated with accumulation of PI 3-kinase products in transformed cells. In addition, upon shifting of cells that express ts BCWabl mutant to permissive temperature, we observed time-dependent increase in total PI 3-kinase activity which was evident within 15 minutes and was maximal at 24 hours (see Fig 4A) .
These results show that activation of PI 3-kinase depends on the activation of BCWabl tyrosine kinase.
We further examined the content and subcellular distribution of p85 in parental and transformed hematopoietic cells by Western blotting. Because two isoforms of p85 (a or 0)
can regulate the activity of the catalytic subunit, we used antibodies that recognize both p85 isoforms. Neither p85 content nor subcellular distribution was significantly altered in BCWabl transformed BaF3 cells when compared with parental cells (Fig 3) . In contrast to the lack of significant change in subcellular distribution of p85, PI 3-kinase activity increased more than twofold in membrane fractions of transformed cells compared with results in parental cells ( Table  2 ). These data suggest that intrinsic activation of the enzyme
in membrane fractions of transformed cells, although translocation of a small fraction of highly active enzyme to membrane fractions cannot be ruled out.
Association of PI 3-kinase activih with BCWa6I. To determine the role of PI 3-kinase association to BCWabl in PI 3-kinase activation and the mechanism of this interaction, we analyzed immunoprecipitable activity in cells expressing ts p210 BCWabl which lacks the YXXM motif, and compared these findings to cells that express the wt BCWabl gene product and parental cells. Figure 4B and C show timedependent increase in PI 3-kinase activity in anti-P-tyr and anti-ab1 immunoprecipitates from cells expressing wt and ts BCWabl mutant after shift to 33°C for indicated times. Phospholipids extracted from metabolically labeled cells were deacylated and identified by HPLC. The amount of PI 3,4-Pz and PIP3 was normalized to the sum of phosphate incorporated into PI 4-P plus PI 4.5-Pz. Combined data for 4 experiments ab1 mutant grown at 33°C for 24 hours had over 20-fold increase in anti-P-tyr immunoprecipitable PI 3-kinase when compared with results from parental cells. The increase in PI 3-kinase activity was also evident in anti-ab1 immunoprecipitates with a maximal increase of sevenfold to eightfold detected in ts BCWabl-expressing cells maintained at permissive temperature for 24 hours. Similar data were obtained for 32D cells expressing the wt and rs BCWabl with a maximal increase after 24 hours at permissive temperature in anti-P-tyr immunoprecipitates (15 5 3-and 17 t 9-fold, respectively) and anti-ab1 immune complexes (5 t 1.3-and 6 5 1.7-fold, respectively) compared with results in parental 32D cells. Differences in affinities of antibodies or stability of these complexes may account for higher levels of PI 3-kinase detected in anti-P-tyr immunoprecipitates. However, For personal use only. on October 27, 2017. by guest www.bloodjournal.org From PI 3-kinase activity in whole-cell extracts and subcellular fractions was measured as U/mg (pmol of "P incorporated into PIPS) as described in Materials and Methods. All data were obtained from duplicate samples. The results are presented as mean (+SI)) from three to five independent experiments and presented as percent control (parental cells).
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we postulate that only a fraction of activated PI 3-kinase forms a complex with BCWabl tyrosine kinase whereas a large portion of activated enzyme is associated with other tyrosine-phosphorylated proteins. In addition, anti-ab1 immune complexes contained similar amounts of PI 3-kinase activity in cells that express wt and ts BCWabl proteins after 24 hours at permissive temperature. Therefore, the lack of YXXM motif in rs p210 BCWabl gene product did not alter the association of BCWabl with activated PI 3-kinase.
We also tested whether association of PI 3-kinase activity correlated with p85 content in anti-P-tyr and anti-ab1 immune complexes (Fig 5A and B, respectively) . We detected a time-dependent increase in association with p85 in ts BCW abl-expressing cells which were shifted to permissive temperature for indicated times while no significant association occurred in these cells maintained at 39°C (TSM 0 [temperature-sensitive mutant at time 01). These data indicate that active tyrosine kinase of BCWabl is necessary for its interaction with p85.
Mechanism of association of p85 with BCWabl. We fur- ther confirmed the association of the wt and rs BCWabl gene products with p85 in vivo by Western blotting. Equal amounts of wt p210 and rs BCWabl protein from cells maintained at permissive temperature for 24 hours (Fig 6, lanes  1 and 2) were used for p85 immunoprecipitation and domainbinding studies (Materials and Methods). Association of BCWabl with p85 in immunoprecipitates was evident in cells that express wt or rs BCWabl mutant. Slightly higher amounts (20% to 30%) of p210 BCWabl in anti-p85 immune complexes was detected consistently in several experiments from cells expressing wt BCWabl gene product compared with f s mutant (Fig 6, lanes 3 and 4) . Anti-p85 immune complexes could contain p210 BCWabl by a direct binding of p85 SH2 domains (to the one YXXM motif) or because of formation of multimolecular complexes containing other adaptor (intermediate) proteins. To determine whether there is a direct interaction between p85 SH2 domains and BCWabl, we performed in vitro binding of immobilized GST-p85 SH2 fusion proteins in cell lysates from cells expressing wt or rs BCWabl gene product maintained at permissive temperature for 24 hours. p85 SH2 domains bound to the wt BCWabl (lanes 5 and 7) whereas virtually no binding was consistently found to ts BCWabl mutant (lanes 6 and 8) . The faint band of rs BCWabl protein associated with p85 C-SH2 domain could represent secondary interactions. We found that the C-terminal SH2 domain has higher affinity for BCWabl compared with N-terminal domain (compare lanes 5 and 7), which is consistent with a previous report that the C-SH2 domain of p85 has higher affinity for tyrosine-phosphorylated proteins.'" These data indicate that direct binding of p85 SH2 domains to p210 BCWabl requires YXXM motif and the mutation of Y to H in p210 BCWabl impairs this interaction.
DISCUSSION
The best-understood mechanism of PI 3-kinase activation is described in response to platelet-derived growth factor and insulin receptor tyrosine kinases. Both involve binding of p85 SH2 domains to phosphotyrosine in YXXM mo- In the present study, we found that activation of PI 3-kinase also occurs in p210 BCWabl-transformed hematopoietic cells. expressing PI 3-kinase wt p210 activity BCWabl was than several-fold parental cells higher as measured in cells by increase in total and membrane-associated enzymatic activity and accumulation of PI 3-kinase products in intact cells.
Because BCWabl fusion protein contains only one YXXM motif, we investigated whether a direct binding of p85 involves p85 SH2 domains and whether this interaction is required for PI 3-kinase activation. The generation of hematopoietic cell lines that express BCR/abl ts mutant enabled us to investigate the role of this motif in PI _?-kinase activation. The generation of BCWabl as a temperature-sensitive mutant was similar to v-ah/ ts mutar~ts~~-'~ and involved substitution of ArgJ5' to His and Tyr4'" to His in c-cthl." The mutation of Tyrd6' modified the only YXXM motif in the p210 BCR/abl sequence. Temperature-sensitive mutants of oncogenic tyrosine kinases have been used extensively to determine the primary biologic effects of their expression. Expression of ts p210 BCRIabl at permissive temperature in murine IL-3-dependent myeloid cell line, BaF3, induced rapid phosphorylation of multiple intracellular substrates. A small increase in the amount of 1.7 BCR/abl gene product was detected after cells were maintained at permissive temperature for 24 hours, which could be caused by increased transcription or stability of the BCRIabl gene product. Similar observations have been reported for the same ts BCRI ab1 construct expressed in murine IL-3-dependent 32D cells" and for a different r s BCR/abl mutant expressed in BaF3 cells.39 Despite expression of rs p210 BCRIabl at nonpermissive temperature, the levels of total and immunoprecipitable PI 3-kinase activity were low and comparable to measurements obtained in parental cells. Rapid and time-dependent increase in PI 3-kinase activity was observed after shifting the cells to permissive temperature and correlated with increase in tyrosine-phosphorylated cellular proteins. These data show, for the first time, that activation of PI .?-kinase in hematopoietic cells requires BCRIabl tyrosine kinase activity.
In addition. these results suggest that interaction of p85 SH2 domains with the YXXM motif in BCR/abl is not required for in vivo activation of PI 3-kinase. The lack of direct binding of ts BCRIabl gene product to p85 SH2 domains was confirmed by in vitro analysis. Although p85 co-immunoprecipitated with wt and ts BCRIabl proteins after 24 hours of maintaining these cells at permissive temperature, p85 SH2 domain GST-fusion protein bound only to the wt but not ts BCRIabl gene product. Therefore. binding of PI 3-kinase to p210 BCRIabl can occur by interaction of p85 SH2 domain and the YXXM motif in BCRIabl. However, activation of PI 3-kinase was detected in cells expressing the ts BCRIabl gene product that does not bind p85 SH2 domains. Therefore, PI 3-kinase binding to BCRIabl is not necessary for PI 3-kinase activation.
Additional information which suggests that interaction of BCWabl and PI 3-kinase is not responsible for PI 3-kinase activation is provided from analysis of fibroblast cell lines which express BCRIabl variants. Although PI 3-kinase activity associates in immunoprecipitates with nontransforming and transforming ah/ variants, only transformed cells have evidence of in vivo activation of the enzyme. They accumulate PI 3-kinase products, PI-3,4P2 and PI-3,4,5P3, and have an increase in PI 3-kinase activity in whole-cell extracts and membrane fractions. Targeted expression to the plasma membrane of gagBCR/abl construct in NIH 3T3 fibroblasts provides access of PI 3-kinase to its substrates, whereas expression of the cytosolic CML protein, p210 BCRIabl, in fibroblasts does not lead to activation of PI 3-kinase or transformation. Lack of PI 3-kinase activation despite association in immune precipitates with PI 3-kinase activity has also been reported for other mitogenically impaired tyrosine kinases expressed in adherent cells, such as mutants of the insulin receptor and polyoma middle T.' ".' ' In this study, we observed that, despite cytosolic localization of BCRIabl tyrosine kinase in hematopoietic cells, PI 3-kinase is activated in intact cells. These observations suggest that differences in signal transduction rather than physical interaction of PI 3-kinase with BCRIabl protein are responsible for activation of PI %kinase in transformed hematopoietic cells.
In contrast to PDGF-induced shift of p85 subunit to membrane fraction^'^ and translocation of p85 to specific membrane fractions in response to insulin? we found no significant change in subcellular distribution of p85 subunit in BCW abl-transformed hematopoietic cells. Although we cannot exclude that a fraction of activated enzyme is transferred to the membrane fraction in transformed cells, we found no evidence of a significant shift of p85 from the cytosol to the membrane fraction. These data also suggest that PI 3-kinase activation in membrane fractions occurs in association with tyrosinephosphorylated proteins other than BCRIabl gene product.
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From The higher levels of PI 3-kinase activity observed in anti-P-tyr than in anti-ab1 immunoprecipitates suggest that anti-P-tyr immune complexes contain other intermediate proteins that may stabilize the complex or recruit additional PI 3-kinase activity. Association of BCIUabl with GRB2, Shc, crWcrkL, and ~-~b 1~~~~~~~ has been described. Interactions of p85 with GRB2, Shc, and cb129.47-49 have also been reported. Whether intermediate proteins bind to PI 3-kinase and are responsible for its activation in BCIUabl transformed hematopoietic cells remains to be determined. Because these interactions involve SH2 and SH3 domains, it is likely that multiple intermediate proteins serve to amplify BCIUabl tyrosine kinase signaling and participate in regulation of PI 3-kinase activity.
